Together we will beat cancer

Donate

PARG inhibitors: tipping the scales with a new experimental drug

Our scientists are developing a new experimental drug to target how cancer cells repair their DNA, and upset cancer’s balance.

Read More

More breast cancer patients than previously thought could benefit from existing targeted treatment

As many as 1 in 5 women with breast cancer could benefit from a drug used to treat ovarian cancer, according to new estimates.

Read More

Ovarian cancer drug could target gene fault in brain tumours

A genetic flaw that’s often found in a type of brain tumour may stop the cells from fixing damage to their DNA, findings from a new US study suggest.

Read More

Future leaders and a lifetime in drug development: our research prizes

Last week we had the pleasure of awarding our Research Prizes to five exceptional researchers at our annual prizegiving ceremony at the NCRI Conference.

Read More

How your support is helping us beat breast cancer – Margaret’s story

The year is 2016, Breast Cancer Awareness Month is upon us, and right now, 8 in 10 women diagnosed with breast cancer will survive their disease for 10 years or more.

Read More

CRT and SV Life Sciences form Artios Pharma to focus on DNA damage response

Cancer Research Technology (CRT) and SV Life Sciences have today announced the launch of Artios Pharma.

Read More

Crashing cancer’s backup system – our progress so far

Research by our scientists played a major part in the development of a promising new class of cancer drugs. So where are we now in this research journey?

Read More

Study opens door to targeted treatments for oesophageal cancer

Scientists have discovered that oesophageal cancer can be classified into three different subtypes, paving the way for testing targeted treatments.

Read More

All women with ovarian cancer should be offered genetic testing – so why aren’t they?

Recent research has reinforced the need for all women with ovarian cancer to receive genetic testing, but they aren’t. We explore why.

Read More

A celebrated career in DNA repair: Tomas Lindahl

We look at how Tomas Lindahl’s discoveries have profoundly changed our understanding of cell response to cytotoxic therapies and the implications of this.

Read More